Radiotherapy to the prostate and metastases in prostate cancer with few metastases
Follows men with prostate cancer and up to 10 metastases after radiotherapy.
Plain-language title generated from the registry record
Registry title: Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer
Key facts
- Where
- Zamość, PolandSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry follows men with prostate cancer that had already spread to up to 10 places at diagnosis. They were treated with radiotherapy to the prostate and to every spread site.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Prostate adenocarcinoma with spread (metastases) found at first diagnosis or within 6 months, in up to 10 sites outside the pelvic region.
- Earlier treatment
- Radiotherapy aimed at removing the disease in the prostate, plus stereotactic body radiotherapy (SBRT) or similar to all spread sites. No other full treatment of the prostate cancer before the spread was found.
Main reasons for not taking part
- More than 10 spread sites at the start
- Only some of the spread sites were treated
- Radiotherapy to the prostate was given only to ease symptoms
- Key treatment or follow-up dates are missing
- Tumour type other than prostate adenocarcinoma
Read by machine on 12 November 2026.
Where in Poland
- Affidea NU-MED Center of Oncological Diagnostics and TherapyZamość, PolandContact: Mateusz Bilski, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
- Trial code
- NCT07686016
- Record updated
- 6 July 2026
- Original description
This is an ambispective, multicenter, observational real-world registry of patients with synchronous de novo oligometastatic prostate cancer, defined as prostate cancer with up to 10 extraregional metastatic lesions diagnosed at initial presentation or within 6 months of the primary diagnosis.Read full original descriptionShow less
Outcomes and Patterns of Failure After Definitive Prostate-Directed Radiotherapy and Metastasis-Directed Therapy in Patients With Synchronous De Novo Prostate Cancer and Up to 10 Metastases: An Ambispective Multicenter Real-World Evidence Registry
This is an ambispective, multicenter, observational real-world registry of patients with synchronous de novo oligometastatic prostate cancer, defined as prostate cancer with up to 10 extraregional metastatic lesions diagnosed at initial presentation or within 6 months of the primary diagnosis.
The study will evaluate outcomes after comprehensive local and metastasis-directed treatment. Eligible patients receive definitive prostate-directed radiotherapy, which may include external-beam radiotherapy, external-beam radiotherapy with brachytherapy boost, or definitive prostate brachytherapy monotherapy in selected patients, together with stereotactic body radiotherapy to all identified extraregional metastatic lesions. Systemic therapy is given according to routine clinical practice and local multidisciplinary decisions.
The registry is non-interventional. Participants are not assigned to treatment by the study protocol, and no experimental treatment, randomization, or protocol-mandated imaging schedule is used. The study collects de-identified data from routine medical records, including baseline disease characteristics, imaging, radiotherapy details, systemic therapy, radiographic progression, patterns of failure, subsequent treatments, adverse events, and survival.
The study includes historical retrospective data, prospective follow-up of previously treated eligible patients, and prospective enrollment of newly eligible patients from the registry activation date. The main goal is to describe where and when prostate cancer progresses after comprehensive treatment of the prostate and all visible metastatic lesions, and to identify clinical and treatment-related factors associated with disease control and adverse events.
Inclusion: Histologically confirmed adenocarcinoma of the prostate; Male sex; Age 18 years or older; Synchronous de novo metastatic prostate cancer diagnosed at initial presentation or within 6 months of primary prostate cancer diagnosis; Up to 10 extraregional metastatic lesions on staging imaging used for clinical decision-making; Treatment with definitive prostate-directed radiotherapy, including external-beam radiotherapy alone, external-beam radiotherapy with brachytherapy boost, or definitive prostate brachytherapy monotherapy in selected patients; Treatment with SBRT or another ablative metastasis-directed radiotherapy approach to all identified extraregional metastatic lesions; Availability of sufficient clinical, imaging, radiotherapy, systemic therapy, follow-up, adverse event, and survival data for outcome assessment; For prospectively enrolled patients, ability to provide informed consent where required by local ethics and regulatory procedures.
Exclusion: Incomplete metastasis-directed therapy, defined as treatment of selected metastatic lesions only while leaving other known baseline extraregional metastatic sites untreated; Prostate-directed radiotherapy delivered with palliative rather than definitive intent; Missing key dates preventing outcome determination, including prostate-directed radiotherapy, brachytherapy, metastasis-directed SBRT dates, or follow-up information; Prior definitive treatment of prostate cancer before diagnosis of synchronous metastatic disease; More than 10 extraregional metastatic lesions at baseline staging; Histology other than adenocarcinoma of the prostate.